BD
Medical devices and connected systems spanning everyday care, drug delivery, monitoring, and intervention.
Something off on this page? Send us feedback.
Profile
Develops devices and consumables for medication delivery, specimen collection, patient monitoring, biopharma drug delivery, and surgical and vascular intervention. Revenue spans four segments and a global customer base, with recurring consumables alongside installed infusion, dispensing, and monitoring systems.
Develops and manufactures medical supplies and devices through Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The portfolio spans vascular-access and specimen-collection products; Alaris infusion and Pyxis medication-management systems; advanced patient monitoring; prefillable syringes and self-injection components; and urology, peripheral-vascular, oncology, and surgical tools.
Sells worldwide to hospitals and clinics, laboratories, pharmaceutical manufacturers, and other care providers, with the United States generating most revenue. Installed infusion, dispensing, and monitoring systems pair with recurring demand for disposable supplies and consumables.
Scale in high-volume essentials combines with integrated medication workflows, while acquired monitoring and interventional platforms broaden clinical coverage. Demand and market access depend on healthcare purchasing and reimbursement, regulatory authorizations and quality-system compliance, and access to raw materials, components, and sterilization capacity.
Company facts
Categories
Key statistics
Year to date +23.7% · Average volume (30d) 1.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 13, 2026 | RBC Capital | Reiterate | Sector Perform | $180 | $190 |
| Aug 7, 2026 | Stifel Nicolaus | Target | $215 | $195 | |
| Aug 7, 2026 | RBC Capital | Reiterate | Sector Perform | $175 | $180 |
| Aug 6, 2026 | Jefferies | Reiterate | Buy | $210 | |
| Jul 28, 2026 | UBS | Initiate | Buy | $190 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q3 FY26 | $3.14 | $3.23 | +2.9% | $4.89B | $4.98B | +2.0% | +3.76% |
| May 7, 2026Q2 FY26 | $2.78 | $2.90 | +4.3% | $4.67B | $4.71B | +0.9% | −2.50% |
| Feb 9, 2026Q1 FY26 | $2.21 | $2.91 | +31.7% | $5.15B | $4.49B | −12.8% | +5.30% |
| Nov 6, 2025Q4 FY25 | $3.92 | $3.96 | +1.0% | $5.91B | $5.89B | −0.3% | +0.25% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.27B | $5.51B | $5.89B | $5.25B | $4.71B | $4.98B | |
| Gross profit | $2.26B | $2.63B | $2.80B | $2.34B | $2.15B | $2.32B | |
| Operating income | $546.0M | $882.0M | $697.0M | $594.0M | $94.0M | $663.0M | |
| Net income | $308.0M | $574.0M | $493.0M | $382.0M | −$311.0M | $377.0M | |
| Diluted EPS | $1.07 | $2.00 | $1.72 | $1.34 | −$1.11 | $1.37 | |
| Gross margin | 42.8% | 47.8% | 47.5% | 44.6% | 45.7% | 46.5% | |
| Operating margin | 10.4% | 16.0% | 11.8% | 11.3% | 2.0% | 13.3% |
Fiscal years (4-quarter sums)FY21 $19.96B · FY22 $18.87B · FY23 $19.37B · FY24 $20.18B · FY25 $21.84B
Revenue by product · Q1 FY26
Revenue by geography · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $709.0M · Total debt $16.81B · Total assets $50.73B · Shareholders' equity $24.42B
Dividends
Raised for 42 straight years — most recently to $1.05 from $0.8252 split-adjusted in Mar 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 9, 2026 | Jun 9 | Jun 30 | $1.05 | |
| Mar 10, 2026 | Mar 10 | Mar 31 | $1.05 | raised from $0.8252 split-adjusted |
| Dec 8, 2025 | Dec 8 | Dec 31 | $1.05 | raised from $1.04 |
| Sep 8, 2025 | Sep 8 | Sep 30 | $1.04 | raised from $1.04 |
| Jun 9, 2025 | Jun 9 | Jun 30 | $1.04 | cut from $1.04 split-adjusted |
| Mar 10, 2025 | Mar 10 | Mar 31 | $1.04 | raised from $0.8176 split-adjusted |
| Dec 9, 2024 | Dec 9 | Dec 31 | $1.04 | cut from $0.95 split-adjusted |
| Sep 9, 2024 | Sep 9 | Sep 30 | $0.95 | raised from $0.7469 split-adjusted |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 275.54M · Float 274.94M · 99.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 24.59M | 8.93% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 17.99M | 6.53% | 13F | Aug 13, 2026 |
| State Street Corp | 15.00M | 5.44% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 14.97M | 5.43% | 13F | Aug 13, 2026 |
| First Eagle Investment Management, LLC | 13.82M | 5.01% | 13F | Aug 24, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Michael Feld | officer: EVP, Chief Revenue Officer | −165 | $188.49 |
| Aug 13, 2026 | Thomas E. Jr Polen | director, officer: Chairman, CEO and President | −4,152 | $185.00 |
| Aug 11, 2026 | Roland Goette | officer: EVP and President, EMEA | −2,438 | $180.84 |
| Jul 27, 2026 | Michael Feld | officer: EVP, Chief Revenue Officer | −75 | $157.13 |
| Jun 26, 2026 | Michael Feld | officer: EVP, Chief Revenue Officer | −75 | $152.80 |
Peers
- Boston Scientific
Head-to-head in interventional vascular, urology, and oncology procedures.
- Baxter International
Direct infusion pump rival; Spectrum IQ contests Alaris for hospital contracts.
- Medtronic
Broadest medtech rival in vascular intervention, surgical, and GPO contracting.
- Johnson & Johnson
MedTech rival in surgical biosurgery, vascular, and hospital procedural markets.
- ICU Medical
Pure-play infusion rival; Plum pumps and LifeShield software contest Alaris.
- Teleflex
Vascular access rival; Arrow brand contests BD's PICC and central catheter lines.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Baxter International | $26.30 | +0.65% | $13.51B | — | 12.5 | 1.2 | +5.3% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| ICU Medical | $175.10 | +0.01% | $4.38B | 148.4 | 19.7 | 2.0 | −0.2% |
| Teleflex | $139.67 | −0.01% | $6.18B | — | 15.2 | 2.4 | −27.0% |
| Median | 27.8 | 15.2 | 2.8 | +6.0% |